Myriad Genetics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - MYGN
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. for potential securities law violations after UnitedHealth Group announced it would stop covering Myriad's GeneSight test starting January 1, 2025.
November 05, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Myriad Genetics is under investigation for potential securities law violations after UnitedHealth announced it would cease coverage for GeneSight, a key product, starting January 2025.
The investigation by Levi & Korsinsky into Myriad Genetics for potential securities law violations is significant, especially following UnitedHealth's decision to stop covering GeneSight. This could negatively impact Myriad's revenue and investor confidence, leading to a potential short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100